

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11068-035-999

APPLICATION NO

09/591,899

APPLICANT

Parkin et al.

FILING DATE

June 12, 2000

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01	5,766,842	6/16/98	Melnick et al.			


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A02	Dreyer GB, et al. "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically" <i>Biochemistry</i> (1993) 32:937-947
A03	J. Eron, et al., Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors," <i>5th Conference on Retroviruses and Opportunistic Infections</i> : (1995) 6
A04	Hill, A. et al. (1998) "Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar," <i>Int. Conf. AIDS</i> 12:812, (Abstract No. 6)
A05	E. E. Kim, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme," <i>J. Am. Chem. Soc.</i> , 117: 1181-1182
A06	Lambert DM, et al. (1992) "Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells" <i>Antimicrob Agents Chem</i> 36:982-98
A07	Brendan A. Larder, et al., (1995) "Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy," <i>Science</i> , 269; 696-699
A08	Janis K. Lazdins, et al., (1997) "In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study with Other Relevant HIV Protease Inhibitors," <i>J Infect. Dis.</i> , 175: 1063-1070
A09	David J. Livingston, et al., (1995) "Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy," <i>J Infect. Dis.</i> , 172:1.238-124
A10	Bhuvaneshwari Mahalingam, et al., (1999) "Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease," <i>Biochem.</i> , 263: 1-9
A11	Miller M, et al. (1989) "Structure of Complex of Synthetic HIV-1 Protease with a SubstrateBased Inhibitor at 2.3 Å Resolution," <i>Science</i> 246:1149-1152
A12	Mohri H, et al. (1993) "Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients," <i>PNAS</i> 90:25-29
A13	Robert L. Murphy, et al., (1999) "Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection" <i>J. Infect. Dis.</i> , 179: 808-81 E
A14	Najera I, et al. (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates," <i>Aids Res Hum Retroviruses</i> 10:1479-1488
A15	Najera I, et al. (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in Virus From Patients Undergoing No Drug Therapy," <i>J Virol</i> 69:23-31
A16	Sarah Palmer, et al., (1999) "Highly Drug-resistant HIV-1 Clinical Isolates Are Cross-resistant to Many Antiretroviral Compounds in Current Clinical Development," <i>AIDS</i> , 13: 661-667
A17	Neil T. Parkin, et al., (1999) "Phenotypic changes in Drug Susceptibility Associated with Failure of Human Immunodeficiency Virus Type 1 (HIV-1) Triple Combination Therapy," <i>J Infect. Dis.</i> , 180: 865-870
A18	Judith A. Partaledis, et al., (1995) "In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Isolates with Reduced Sensitivity to Hydroxyethylamino Sulfonamide Inhibitors of HIV-1 Aspartyl Protease," <i>Journal of Virology</i> , 69: 5228-5235

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY DOCKET NO.	APPLICATION NO
	11068-035-999	09/591,899
	APPLICANT	
	Parkin et al.	
	FILING DATE	GROUP
	June 12, 2000	1648

A19	Petit SC, <i>et al.</i> (1993) "The Specificity of the HIV-1 Protease" <i>Drug Discov Des</i> 1:69-83
A20	Roberts NA, <i>et al.</i> (1990) "Rational Design of Peptide-Based HIV Proteinase" <i>Science</i> 248:358361
A21	Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors," <i>AIDS</i> 9 (supp 2) S27-S32
A22	Brian M. Sadler, <i>et al.</i> , (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults," <i>Antimicrobial Agents and Chemotherapy</i> , 43: 1686-1692
A23	Sarkar G. and Sommer SS., (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>BioTech</i> 8(4):404-407
A24	Mary L. Smidt, <i>et al.</i> , (1996) "A Mutation in Human Immunodeficiency Virus Type 1 Protease at Position 88, Located Outside the Active Site, Confers Resistance to the Hydroxyethylurea Inhibitor SC-55389A," <i>Antimicrobial Agents and Chemotherapy</i> , 41: 515-522
A25	M. H. St. Clair, <i>et al.</i> , (1996) "In Vitro Antiviral Activity of 141 W94 (VX-478) in Combination with Other Antiretroviral Agents," <i>Antiviral Research</i> 29: 53-56
A26	H. Tian, <i>et al.</i> , (1998) "Zidovudine/Lamivudine Co-resistance Is Preceded by a Transient Period of Zidovudine Hypersensitivity," 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 30
A27	Tisdale, M. <i>et al.</i> (1998): "Genotypic and phenotypic analysis of HIV from patients on ZDV/3TC/amprenavir combination therapy," <i>Int. Conf AIDS</i> 12:583 (Abstract No. 32312)
A28	Simon P. Tucker, <i>et al.</i> , (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 42: 478-480

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	